Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines
Abstract Primary effusion lymphoma (PEL) and a form of multicentric Castleman’s disease (MCD) are both caused by Kaposi sarcoma herpesvirus (KSHV). There is a critical need for improved therapies for these disorders. The IL-6/JAK/STAT3 pathway plays an important role in the pathogenesis of both PEL...
Main Authors: | Yiquan Wu, Victoria Wang, Robert Yarchoan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-024-54453-7 |
Similar Items
-
Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
by: Chiara Ghezzi, et al.
Published: (2023-01-01) -
Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma
by: Hilmar Quentmeier, et al.
Published: (2022-01-01) -
Indolent primary effusion lymphoma
by: Vidya Nagrale, et al.
Published: (2020-07-01) -
Profile of pacritinib and its potential in the treatment of hematologic disorders
by: Hatzimichael E, et al.
Published: (2014-08-01) -
Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
by: Prabha Shrestha, et al.
Published: (2021-01-01)